BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 32781289)

  • 1. A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes.
    Nazha A; Hu ZH; Wang T; Lindsley RC; Abdel-Azim H; Aljurf M; Bacher U; Bashey A; Cahn JY; Cerny J; Copelan E; DeFilipp Z; Diaz MA; Farhadfar N; Gadalla SM; Gale RP; George B; Gergis U; Grunwald MR; Hamilton B; Hashmi S; Hildebrandt GC; Inamoto Y; Kalaycio M; Kamble RT; Kharfan-Dabaja MA; Lazarus HM; Liesveld JL; Litzow MR; Majhail NS; Murthy HS; Nathan S; Nishihori T; Pawarode A; Rizzieri D; Sabloff M; Savani BN; Schachter L; Schouten HC; Seo S; Shah NN; Solh M; Valcárcel D; Vij R; Warlick E; Wirk B; Wood WA; Yared JA; Alyea E; Popat U; Sobecks RM; Scott BL; Nakamura R; Saber W
    Biol Blood Marrow Transplant; 2020 Nov; 26(11):2139-2146. PubMed ID: 32781289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Epigenomic Hypermethylation at TP53 on Allogeneic Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndromes.
    Wang W; Auer P; Zhang T; Spellman S; Carlson KS; Nazha A; Bolon YT; Saber W
    Transplant Cell Ther; 2021 Aug; 27(8):659.e1-659.e6. PubMed ID: 33992829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
    Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
    Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematopoietic Cell Transplantation for Myelodysplastic Syndromes.
    Bhatt VR; Steensma DP
    J Oncol Pract; 2016 Sep; 12(9):786-92. PubMed ID: 27621329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome.
    Slade M; DiPersio JF; Westervelt P; Vij R; Schroeder MA; Romee R
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1736-1743. PubMed ID: 28688919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
    Gyurkocza B; Gutman J; Nemecek ER; Bar M; Milano F; Ramakrishnan A; Scott B; Fang M; Wood B; Pagel JM; Baumgart J; Delaney C; Maziarz RT; Sandmaier BM; Estey EH; Appelbaum FR; Storer BE; Deeg HJ
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):549-55. PubMed ID: 24440648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.
    Lindsley RC; Saber W; Mar BG; Redd R; Wang T; Haagenson MD; Grauman PV; Hu ZH; Spellman SR; Lee SJ; Verneris MR; Hsu K; Fleischhauer K; Cutler C; Antin JH; Neuberg D; Ebert BL
    N Engl J Med; 2017 Feb; 376(6):536-547. PubMed ID: 28177873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TP53 Mutations Are Associated with Increased Infections and Reduced Hematopoietic Cell Transplantation Rates in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
    Marvin-Peek J; Mason EF; Kishtagari A; Jayani RV; Dholaria B; Kim TK; Engelhardt BG; Chen H; Strickland S; Savani B; Ferrell B; Kassim A; Savona M; Mohan S; Byrne M
    Transplant Cell Ther; 2023 Jun; 29(6):390.e1-390.e10. PubMed ID: 36906277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study.
    Versluis J; Saber W; Tsai HK; Gibson CJ; Dillon LW; Mishra A; McGuirk J; Maziarz RT; Westervelt P; Hegde P; Mukherjee D; Martens MJ; Logan B; Horowitz M; Hourigan CS; Nakamura R; Cutler C; Lindsley RC;
    J Clin Oncol; 2023 Oct; 41(28):4497-4510. PubMed ID: 37607457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Kongtim P; Parmar S; Milton DR; Perez JMR; Rondon G; Chen J; Chilkulwar AR; Al-Atrash G; Alousi A; Andersson BS; Im JS; Hosing CM; Bashir Q; Khouri I; Kebriaei P; Oran B; Popat U; Champlin R; Ciurea SO
    Bone Marrow Transplant; 2019 Jun; 54(6):839-848. PubMed ID: 30258129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.
    Deeg HJ; Scott BL; Fang M; Shulman HM; Gyurkocza B; Myerson D; Pagel JM; Platzbecker U; Ramakrishnan A; Radich JP; Sandmaier BM; Sorror M; Stirewalt DL; Wilson WA; Storb R; Appelbaum FR; Gooley T
    Blood; 2012 Aug; 120(7):1398-408. PubMed ID: 22767498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic landscape of mitochondrial genome in myelodysplastic syndrome after stem-cell transplantation.
    Dong J; Buradagunta CS; Zhang T; Spellman S; Bolon YT; DeZern AE; Gadalla SM; Deeg HJ; Nazha A; Cutler C; Cheng C; Urrutia R; Auer P; Saber W
    J Hematol Oncol; 2023 Mar; 16(1):21. PubMed ID: 36899395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation.
    Koenecke C; Göhring G; de Wreede LC; van Biezen A; Scheid C; Volin L; Maertens J; Finke J; Schaap N; Robin M; Passweg J; Cornelissen J; Beelen D; Heuser M; de Witte T; Kröger N;
    Haematologica; 2015 Mar; 100(3):400-8. PubMed ID: 25552702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of somatic mutations with outcome after FLAMSA-busulfan sequential conditioning and allogeneic stem cell transplantation in patients with myelodysplastic syndromes.
    Christopeit M; Badbaran A; Alawi M; Zabelina T; Zeck G; Wolschke C; Ayuk F; Kröger N
    Eur J Haematol; 2016 Sep; 97(3):288-96. PubMed ID: 26680262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis.
    Michelis FV; Gupta V; Zhang MJ; Wang HL; Aljurf M; Bacher U; Beitinjaneh A; Chen YB; DeFilipp Z; Gale RP; Kebriaei P; Kharfan-Dabaja M; Lazarus HM; Nishihori T; Olsson RF; Oran B; Rashidi A; Rizzieri DA; Tallman MS; de Lima M; Khoury HJ; Sandmaier BM; Weisdorf D; Saber W;
    Cancer; 2017 Jun; 123(11):2035-2042. PubMed ID: 28117898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation.
    Heuser M; Gabdoulline R; Löffeld P; Dobbernack V; Kreimeyer H; Pankratz M; Flintrop M; Liebich A; Klesse S; Panagiota V; Stadler M; Wichmann M; Shahswar R; Platzbecker U; Thiede C; Schroeder T; Kobbe G; Geffers R; Schlegelberger B; Göhring G; Kreipe HH; Germing U; Ganser A; Kröger N; Koenecke C; Thol F
    Ann Hematol; 2017 Aug; 96(8):1361-1372. PubMed ID: 28612220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation.
    Yoshizato T; Nannya Y; Atsuta Y; Shiozawa Y; Iijima-Yamashita Y; Yoshida K; Shiraishi Y; Suzuki H; Nagata Y; Sato Y; Kakiuchi N; Matsuo K; Onizuka M; Kataoka K; Chiba K; Tanaka H; Ueno H; Nakagawa MM; Przychodzen B; Haferlach C; Kern W; Aoki K; Itonaga H; Kanda Y; Sekeres MA; Maciejewski JP; Haferlach T; Miyazaki Y; Horibe K; Sanada M; Miyano S; Makishima H; Ogawa S
    Blood; 2017 Apr; 129(17):2347-2358. PubMed ID: 28223278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation.
    Bejar R; Stevenson KE; Caughey B; Lindsley RC; Mar BG; Stojanov P; Getz G; Steensma DP; Ritz J; Soiffer R; Antin JH; Alyea E; Armand P; Ho V; Koreth J; Neuberg D; Cutler CS; Ebert BL
    J Clin Oncol; 2014 Sep; 32(25):2691-8. PubMed ID: 25092778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of circulating tumor DNA status post-allogeneic hematopoietic stem cell transplantation in AML and MDS.
    Nakamura S; Yokoyama K; Shimizu E; Yusa N; Kondoh K; Ogawa M; Takei T; Kobayashi A; Ito M; Isobe M; Konuma T; Kato S; Kasajima R; Wada Y; Nagamura-Inoue T; Yamaguchi R; Takahashi S; Imoto S; Miyano S; Tojo A
    Blood; 2019 Jun; 133(25):2682-2695. PubMed ID: 30936070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.